drugset / Trial / NCT01498640
Retreatment of Recurrent Dupuytren's Contractures
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The objectives of this study are to assess the safety and efficacy of AA4500 in the retreatment of recurrent contractures in joints that were effectively treated with AA4500 in a previous Auxilium-sponsored Phase 3 study.
Timeline
- Start
- 2012-03
- Primary completion
- 2013-10
- Completion
- 2013-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Collagenase Clostridium Histolyticum | Protein / enzyme biologic | 0.58 mg | — |